Role of p53 family members p73 and p63 in human hematological malignancies

References

• Xu-Monette ZY, Medeiros LJ, Li Y, . Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012 Jan 24. [Epub ahead of print]
   Web of Science ®Google Scholar
• Cheung KJ, Horsman DE, Gascoyne RD. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol 2009;146:257–269.
   PubMed Web of Science ®Google Scholar
• Donehower LA, Harvey M, Slagle BL, . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215–221.
   PubMed Web of Science ®Google Scholar
• Jacks T, Remington L, Williams BO, . Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1–7.
   PubMed Web of Science ®Google Scholar
• Talos F, Moll UM. Role of the p53 family in stabilizing the genome and preventing polyploidization. Adv Exp Med Biol 2010;676:73–91.
   Google Scholar
• Moll UM, Wolff S, Speidel D, . Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol 2005;17:631–636.
   PubMed Web of Science ®Google Scholar
• Rufini A, Agostini M, Grespi F, . p73 in cancer. Genes Cancer 2011;2:491–502.
   PubMedGoogle Scholar
• Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 2011;18:1487–1499.
   PubMedGoogle Scholar
• Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004;2:371–386.
   PubMed Web of Science ®Google Scholar
• Stiewe T, Zimmermann S, Frilling A, . Transactivation-deficient deltaTA-p73 acts as an oncogene. Cancer Res 2002;62:3598–3602.
   PubMed Web of Science ®Google Scholar
• Talos F, Nemajerova A, Flores ER, . p73 suppresses polyploidy and aneuploidy in the absence of functional p53. Mol Cell 2007;27: 647–659.
   Google Scholar
• Li C, Feng Y, Coukos G, . Therapeutic microRNA strategies in human cancer. AAPS J 2009;11:747–757.
   Google Scholar
• Knouf EC, Garg K, Arroyo JD, . An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Res 2012;40:499–510.
   PubMed Web of Science ®Google Scholar
• Agostini M, Tucci P, Killick R, . Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci USA 2011;108:21093–21098.
   PubMed Web of Science ®Google Scholar
• Antonini D, Russo MT, De Rosa L, . Transcriptional repression of miR-34 family contributes to p63-mediated cell cycle progression in epidermal cells. J Invest Dermatol 2010;130:1249–1257.
   PubMed Web of Science ®Google Scholar
• Rao DS, O’Connell RM, Chaudhuri AA, . MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity 2010;33:48–59.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Bottoni A, Shimizu M, . Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. J Am Med Assoc 2011;305:59–67.
   PubMed Web of Science ®Google Scholar
• Su X, Chakravarti D, Cho MS, . TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010; 467:986–990.
   PubMed Web of Science ®Google Scholar
• Rivetti di Val Cervo P, Lena AM, Nicoloso M, . p63-microRNA feedback in keratinocyte senescence. Proc Natl Acad Sci USA 2012; 109:1133–1138.
   PubMed Web of Science ®Google Scholar
• Pekarsky Y, Santanam U, Cimmino A, . Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006;66:11590–11593.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhao LJ, Tan YX, . MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 2012 Mar 13. [Epub ahead of print]
   Web of Science ®Google Scholar
• Yang C, Cai J, Wang Q, . Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol 2012;124: 325–334.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chuang A, Hao H, . Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ 2011;18:1220–1230.
   Google Scholar
• Huang Y, Guerrero-Preston R, Ratovitski EA. Phospho-ΔNp63α-dependent regulation of autophagic signaling through transcription and micro-RNA modulation. Cell Cycle 2012;11:1247–1259.
   PubMed Web of Science ®Google Scholar
• Ory B, Ramsey MR, Wilson C, . A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest 2011;121:809–820.
   PubMed Web of Science ®Google Scholar
• Batliner J, Buehrer E, Fey MF, . Inhibition of the miR-143/145 cluster attenuated neutrophil differentiation of APL cells. Leuk Res 2012;36:237–240.
   PubMed Web of Science ®Google Scholar
• Kent OA, Chivukula RR, Mullendore M, . Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev 2010;24:2754–2759.
   PubMed Web of Science ®Google Scholar
• Yang A, Walker N, Bronson R, . p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000;404:99–103.
   PubMed Web of Science ®Google Scholar
• Flores ER, Sengupta S, Miller JB, . Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005;7:363–373.
   PubMed Web of Science ®Google Scholar
• Nemajerova A, Palacios G, Nowak NJ, . Targeted deletion of p73 in mice reveals its role in T cell development and lymphomagenesis. PLoS One 2009;4:e7784.
   PubMed Web of Science ®Google Scholar
• Griesmann H, Schlereth K, Krause M, . p53 and p73 in suppression of Myc-driven lymphomagenesis. Int J Cancer 2009;124: 502–506.
   PubMed Web of Science ®Google Scholar
• Nemajerova A, Petrenko O, Trümper L, . Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. J Clin Invest 2010;120:2070–2080.
   PubMed Web of Science ®Google Scholar
• Tomasini R, Tsuchihara K, Wilhelm M, . TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008;22:2677–2691.
   PubMed Web of Science ®Google Scholar
• Wilhelm MT, Rufini A, Wetzel MK, . Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 2008;24:549–560.
   Web of Science ®Google Scholar
• Zaika AI, Slade N, Erster SH, . DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002;196:765–780.
   PubMed Web of Science ®Google Scholar
• Sahu GR, Das BR. Alteration of p73 in pediatric de novo acute lymphoblastic leukemia. Biochem Biophys Res Commun 2005;327: 750–755.
   PubMed Web of Science ®Google Scholar
• Meier M, den Boer ML, Meijerink JP, . Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia. Leukemia 2006;20:1377–1384.
   PubMed Web of Science ®Google Scholar
• Corn PG, Kuerbitz SJ, van Noesel MM, . Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5’ CpG island methylation. Cancer Res 1999;59:3352–3356.
   PubMed Web of Science ®Google Scholar
• Liu M, Li R, Hayashi Y, . Study on abnormal expression of the p73 gene in childhood acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi 2002;23:239–242.
   PubMedGoogle Scholar
• Kawano S, Miller CW, Gombart AF, . Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 1999;94:1113–1120.
   PubMed Web of Science ®Google Scholar
• Gutierrez MI, Siraj AK, Bhargava M, . Concurrent methylation of multiple genes in childhood ALL: correlation with phenotype and molecular subgroup. Leukemia 2003;17:1845–1850.
   PubMed Web of Science ®Google Scholar
• Bueso-Ramos C, Xu Y, McDonnell TJ, . Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol 2005;23:3932–3939.
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Jimenez-Velasco A, Agirre X, . Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J Clin Oncol 2005;23:7043–7049.
   PubMed Web of Science ®Google Scholar
• Abd El-Hamid TM, Mossallam GI, Sherisher MA. The clinical implications of methylated p15 and p73 genes in adult acute lymphoblastic leukemia. J Egypt Natl Cancer Inst 2010;22:175–184.
   PubMedGoogle Scholar
• Scaruffi P, Casciano I, Masiero L, . Lack of p73 expression in mature B-ALL and identification of three new splicing variants restricted to pre B and C-ALL indicate a role of p73 in B cell ALL differentiation. Leukemia 2000;14:518–519.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Daniel J, Smith TL, . DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 2002;8:2217–2224.
   PubMed Web of Science ®Google Scholar
• Yang H, Kadia T, Xiao L, . Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 2009;113:1892–1898.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Bueso-Ramos C, Daniel J, . DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res 2002;8:1897–1903.
   PubMed Web of Science ®Google Scholar
• Canalli AA, Yang H, Jeha S, . Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leuk Res 2005;29:881–885.
   PubMed Web of Science ®Google Scholar
• Shen L, Toyota M, Kondo Y, . Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 2003;101:4131–4136.
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Jimenez-Velasco A, Agirre X, . CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia. Clin Cancer Res 2006;12:4845–4850.
   PubMed Web of Science ®Google Scholar
• Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011;25:1010–1022.
   PubMed Web of Science ®Google Scholar
• Novak U, Grob TJ, Baskaynak G, . Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. Ann Oncol 2001;12:981–986.
   PubMed Web of Science ®Google Scholar
• Leupin N, Lüthi A, Novak U, . P73 status in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2004;45:1205–1207.
   PubMed Web of Science ®Google Scholar
• Casabonne D, Reina O, Benavente Y, . Single nucleotide polymorphisms of matrix metalloproteinase 9 (MMP9) and tumor protein 73 (TP73) interact with Epstein-Barr virus in chronic lymphocytic leukemia: results from the European case-control study EpiLymph. Haematologica 2011;96:323–327.
   PubMed Web of Science ®Google Scholar
• Alonso ME, Bello MJ, Gonzalez-Gomez P, . Mutation analysis of the p73 gene in nonastrocytic brain tumours. Br J Cancer 2001;85:204–208.
   PubMed Web of Science ®Google Scholar
• Martinez-Delgado B, Melendez B, Cuadros M, . Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. Int J Cancer 2002;102:15–19.
   PubMed Web of Science ®Google Scholar
• Herranz M, Urioste M, Santos J, . Allelic losses and genetic instabilities of PTEN and p73 in non-Hodgkin lymphomas. Leukemia 2000;14:1325–1327.
   PubMed Web of Science ®Google Scholar
• Stoffel A, Filippa D, Rao PH. The p73 locus is commonly deleted in non-Hodgkin's lymphomas. Leuk Res 2004;28:1341–1345.
   PubMed Web of Science ®Google Scholar
• Cuadros M, Ribas G, Fernández V, . Allelic expression and quantitative RT-PCR study of TAp73 and DeltaNp73 in non-Hodgkin's lymphomas. Leuk Res 2006;30:170–177.
   PubMed Web of Science ®Google Scholar
• van Doorn R, Zoutman WH, Dijkman R, . Epigenetic profiling of cutaneous T-cell lymphoma:promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005;23:3886–3896.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Sakurai S, Hironaka M, . Distinct methylated profiles in Helicobacter pylori dependent and independent gastric MALT lymphomas. Gut 2003;52:641–646.
   PubMed Web of Science ®Google Scholar
• Kondo T, Oka T, Sato H, . Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma. Int J Oncol 2009;35:547–557.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gomez P, Bello MJ, Arjona D, . CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients. Cancer Genet Cytogenet 2003;142:21–24.
   PubMed Web of Science ®Google Scholar
• Chu LC, Eberhart CG, Grossman SA, . Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 2006; 119:2487–2491.
   PubMed Web of Science ®Google Scholar
• Sato H, Oka T, Shinnou Y, . Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. Am J Pathol 2010;176:402–415.
   PubMed Web of Science ®Google Scholar
• Siu LL, Chan JK, Wong KF, . Specific patterns of gene methylation in natural killer cell lymphomas : p73 is consistently involved. Am J Pathol 2002;160:59–66.
   PubMed Web of Science ®Google Scholar
• Siu LL, Chan JK, Wong KF, . Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br J Haematol 2003;122:70–77.
   PubMed Web of Science ®Google Scholar
• Kawamata N, Inagaki N, Mizumura S, . Methylation status analysis of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/Cip1, p27Kip1 and p73) in natural killer cell disorders. Eur J Haematol 2005;74:424–429.
   PubMed Web of Science ®Google Scholar
• Pei JH, Luo SQ, Zhong Y, . The association between non-Hodgkin lymphoma and methylation of p73. Tumour Biol 2011; 32:1133–1138.
   PubMed Web of Science ®Google Scholar
• Hummel M, Bentink S, Berger H, . A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419–2430.
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Clurman B, Appelbaum FR, . p73 mutations and expression in adult de novo acute myelogenous leukemia. Leukemia 1999;13:985–990.
   PubMed Web of Science ®Google Scholar
• Galm O, Wilop S, Reichelt J, . DNA methylation changes in multiple myeloma. Leukemia 2004;18:1687–1692.
   PubMed Web of Science ®Google Scholar
• Hess CJ, Errami A, Berkhof J, . Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. Leuk Lymphoma 2008;49:1132–1141.
   PubMed Web of Science ®Google Scholar
• Galm O, Wilop S, Lüders C, . Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann Hematol 2005;84(Suppl. 1):39–46.
   PubMed Web of Science ®Google Scholar
• Griffiths EA, Gore SD, Hooker CM, . Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics 2010;5:590–600.
   PubMed Web of Science ®Google Scholar
• Talos F, Nemajerova A, Flores ER, . p73 suppresses polyploidy and aneuploidy in the absence of functional p53. Mol Cell 2007;27: 647–659.
   Google Scholar
• Stanganelli C, Arbelbide J, Fantl DB, . DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance. Ann Hematol 2010;89:191–199.
   PubMed Web of Science ®Google Scholar
• Peters UR, Tschan MP, Kreuzer KA, . Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Cancer Res 1999; 59:4233–4236.
   PubMed Web of Science ®Google Scholar
• Tschan MP, Grob TJ, Peters UR, . Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochem Biophys Res Commun 2000;277:62–65.
   PubMed Web of Science ®Google Scholar
• Rizzo MG, Giombini E, Diverio D, . Analysis of p73 expression pattern in acute myeloid leukemias:lack of deltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia 2004;18:1804–1809.
   PubMed Web of Science ®Google Scholar
• Mainardi S, Pelosi A, Palescandolo E, . deltaN-p73 is a transcriptional target of the PML/RARalpha oncogene in myeloid differentiation. Cell Death Differ 2007;14:1968–1971.
   PubMed Web of Science ®Google Scholar
• Bisso A, Collavin L, Del Sal G. p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des 2011;17:578–590.
   PubMed Web of Science ®Google Scholar
• Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007;26: 2220–2225.
   PubMedGoogle Scholar
• Bailey SG, Sanchez-Elsner T, Stephanou A, . Regulating the genome surveillance system: miRNAs and the p53 super family. Apoptosis 2010;15:541–552.
   PubMed Web of Science ®Google Scholar
• Di Leva G, Briskin D, Croce CM. MicroRNA in cancer: new hopes for antineoplastic chemotherapy. Upsala J Med Sci 2012 Feb 21. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Daskalakis M, Blagitko-Dorfs N, Hackanson B. Decitabine. Recent Results Cancer Res 2010;184:131–157.
   PubMedGoogle Scholar
• Litzow MR. Novel therapeutic approaches for acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2011;25:1303–1317.
   PubMed Web of Science ®Google Scholar
• Marks PW. Decitabine for acute myeloid leukemia. Expert Rev Anticancer Ther 2012;12:299–305.
   PubMed Web of Science ®Google Scholar
• Kalac M, Scotto L, Marchi E, . HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 2011;118: 5506–5516.
   PubMed Web of Science ®Google Scholar
• Alhosin M, Sharif T, Mousli M, . Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. J Exp Clin Cancer Res 2011;30:41–50.
   PubMed Web of Science ®Google Scholar
• Mills AA, Zheng B, Wang XJ, . p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708–713.
   PubMed Web of Science ®Google Scholar
• Yang A, Schweitzer R, Sun D, . p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714–718.
   PubMed Web of Science ®Google Scholar
• Keyes WM, Vogel H, Koster MI, . p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc Natl Acad Sci USA 2006;103:8435–8440.
   PubMed Web of Science ®Google Scholar
• Guo X, Keyes WM, Papazoglu C, . TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 2009;11:1451–1457.
   PubMed Web of Science ®Google Scholar
• Graziano V, De Laurenzi V. Role of p63 in cancer development. Biochim Biophys Acta 2011;1816:57–66.
   PubMed Web of Science ®Google Scholar
• Rinne T, Brunner HG, van Bokhoven H. p63-associated disorders. Cell Cycle 2007;6:262–268.
   PubMed Web of Science ®Google Scholar
• Akahoshi K, Sakazume S, Kosaki K, . EEC syndrome type 3 with a heterozygous germline mutation in the P63 gene and B cell lymphoma. Am J Med Genet A 2003;120A:370–373.
   PubMed Web of Science ®Google Scholar
• Cabanillas M, Torrelo A, Monteagudo B, . A novel heterozygous point mutation in the p63 gene in a patient with ectodermal dysplasia associated with B-cell leukemia. Pediatr Dermatol 2011; 28:707–710.
   PubMed Web of Science ®Google Scholar
• Balci S, Engiz O, Okten G, . A 19-year follow-up of a patient with type 3 ectrodactyly-ectodermal dysplasia-clefting syndrome who developed non-Hodgkin lymphoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:e91–e95.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Inokuchi K, Sakuma Y, . Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia. Leukemia 2001;15:1729–1734.
   PubMed Web of Science ®Google Scholar
• Pruneri G, Fabris S, Dell’Orto P, . The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J Pathol 2005;206:337–345.
   PubMed Web of Science ®Google Scholar
• Di Como CJ, Urist MJ, Babayan I, . p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002;8:494–501.
   PubMed Web of Science ®Google Scholar
• Park CK, Oh YH. Expression of p63 in reactive hyperplasias and malignant lymphomas. J Korean Med Sci 2005;20:752–758.
   PubMed Web of Science ®Google Scholar
• Chilosi M, Zamò A, Brighenti A, . Constitutive expression of deltaN-p63alpha isoform in human thymus and thymic epithelial tumours. Virchows Arch 2003;443:175–183.
   PubMed Web of Science ®Google Scholar
• Hedvat CV, Teruya-Feldstein J, Puig P, . Expression of p63 in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol 2005;13:237–242.
   PubMedGoogle Scholar
• Fukushima N, Satoh T, Sueoka N, . Clinico-pathological characteristics of p63 expression in B-cell lymphoma. Cancer Sci 2006;97:1050–1055.
   PubMed Web of Science ®Google Scholar
• Gualco G, Weiss LM, Bacchi CE. Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma. HumPathol 2008;39:1505–1510.
   Google Scholar
• Zuo XL, Zhou Y, Zhou X, . Expression of survivin and P63 protein in B cell non-Hodgkin's lymphoma and their effects on cell apoptosis and proliferation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007;15:99–102.
   PubMedGoogle Scholar
• Hallack Neto AE, Siqueira SA, Dulley FL, . p63 protein expression in high risk diffuse large B-cell lymphoma. J Clin Pathol 2009;62:77–79.
   PubMed Web of Science ®Google Scholar
• Nylander K, Vojtesek B, Nenutil R, . Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002;198:417–427.
   PubMed Web of Science ®Google Scholar
• Alisi A, Giannini C, Spaziani A, . Hepatitis C virus core protein enhances B lymphocyte proliferation. Digest Liver Dis 2007;39 (Suppl. 1):S72–S75.
   Google Scholar
• Serber Z, Lai HC, Yang A, . A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol 2002;22:8601–8611.
   PubMed Web of Science ®Google Scholar
• Ghioni P, Bolognese F, Duijf PH, . Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol 2002;22:8659–8668.
   PubMed Web of Science ®Google Scholar
• Koster MI, Kim S, Mills AA, . p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 2004;18:126–131.
   PubMed Web of Science ®Google Scholar
• Blandino G, Moll UM. p63 regulation by microRNAs. Cell Cycle 2009;8:1466–1467.
   PubMed Web of Science ®Google Scholar
• Manni I, Artuso S, Careccia S, . The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J 2009;23:3957–3966.
   Google Scholar
• Gutiérrez MI, Siraj AK, Ibrahim MM, . Childhood and adult ALL: differences in epigenetic lesions associated with cell cycle genes. Am J Hematol 2005;80:158–160.
   PubMed Web of Science ®Google Scholar
• Toso A, Aluffi P, Capello D, . Clinical and molecular features of mucosa-associated lymphoid tissue (MALT) lymphomas of salivary glands. Head Neck 2009;31:1181–1187.
   PubMed Web of Science ®Google Scholar
• Au WY, Fung A, Ma ES, . HLA associations, microsatellite instability and epigenetic changes in thyroid lymphoma in Chinese. Leuk Lymphoma 2007;48:531–534.
   PubMed Web of Science ®Google Scholar
• Ekmekci CG, Gutiérrez MI, Siraj AK, . Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Hematol 2004;77:233–240.
   PubMed Web of Science ®Google Scholar
• Seidl S, Ackermann J, Kaufmann H, . DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 2004;100:2598–2606.
   PubMed Web of Science ®Google Scholar
• Chim CS, Kwong YL, Fung TK, . Methylation profiling in multiple myeloma. Leuk Res 2004;28:379–385.
   PubMed Web of Science ®Google Scholar